1.

Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier

2.

Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier

3.

Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier

4.

Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier

5.

Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier

1.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

2.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

3.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

4.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

5.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

6.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

7.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

8.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

9.

AON-Mediated Exon Skipping to Bypass Protein Truncation in Retinal Dystrophies Due to the Recurrent CEP290 c.4723A > T Mutation. Fact or Fiction?

1.

Initial Capital Constraints hinder Entrepreneurial Venture Performance

2.

Initial Capital Constraints hinder Entrepreneurial Venture Performance

3.

Initial Capital Constraints hinder Entrepreneurial Venture Performance

1.

Recurrent and founder mutations in the Netherlands:Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy

2.

Recurrent and founder mutations in the Netherlands:Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy

3.

Recurrent and founder mutations in the Netherlands:Phospholamban p.Arg14del mutation causes arrhythmogenic cardiomyopathy

1.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

2.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

3.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

4.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

5.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

6.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

7.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

8.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

9.

Half of 23 Belgian dog breeds has a compromised genetic diversity, as revealed by genealogical and molecular data analysis.

1.

A genome-wide search for genes involved in type 2 diabetes in a recently genetically isolated population from the Netherlands

2.

A genome-wide search for genes involved in type 2 diabetes in a recently genetically isolated population from the Netherlands

3.

A genome-wide search for genes involved in type 2 diabetes in a recently genetically isolated population from the Netherlands

1.

Table1_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

2.

Table1_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

3.

Table1_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

4.

Table1_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

5.

Table1_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

1.

Table2_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

2.

Table2_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

3.

Table2_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

4.

Table2_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX

5.

Table2_Variable clinical expression of a Belgian TGFB3 founder variant suggests the presence of a genetic modifier.DOCX